Mediwound Ltd. key statistics and ratios

In fiscal 2025, Mediwound Ltd. had return on equity of -63.9%, an operating margin of -149.0%, debt equal to 0.0% of equity and a current ratio of 2.33. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Mediwound Ltd.: financial ratios, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Gross margin	—	−38.5%	36.8%	38.6%	62.7%	34.7%	36.9%	49.7%	19.1%	13.0%	19.2%
Operating margin	<−999%	<−999%	−548.4%	−116.4%	14.1%	−40.6%	−47.2%	−31.5%	−81.8%	−95.9%	−149.0%
Net margin	<−999%	<−999%	−887.4%	−31.1%	15.6%	−42.3%	−57.0%	−74.0%	−35.9%	−149.5%	−140.8%
Free-cash-flow margin	<−999%	<−999%	−701.1%	−372.7%	23.6%	−35.9%	−39.6%	−47.0%	−90.6%	−98.4%	−127.5%
Return on equity	−94.1%	−120.9%	—	−11.5%	41.1%	−82.0%	—	—	−31.6%	−96.3%	−63.9%
Return on assets	—	−52.8%	−55.4%	−2.7%	13.1%	−25.7%	−53.3%	−56.2%	−11.5%	−43.2%	−29.9%
Asset turnover	—	0.04	0.06	0.09	0.84	0.61	0.94	0.76	0.32	0.29	0.21
Current ratio	—	6.25	7.64	6.68	3.43	3.17	1.39	3.80	2.74	1.97	2.33
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	—	—	—	—	32.3x	n/m	n/m	n/m	n/m	n/m	n/m
Effective tax rate	—	—	—	—	0.0%	—	—	—	—	—	—
R&D as % of revenue	>999%	453.7%	218.8%	119.7%	15.6%	35.4%	43.2%	38.4%	40.0%	43.9%	84.4%
Capital spending as % of revenue	62.6%	43.1%	41.9%	15.3%	2.5%	4.2%	2.1%	2.1%	34.6%	31.0%	32.5%
Free cash flow ÷ net income	—	—	—	—	151.3%	—	—	—	—	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · December 31, 2025

What it owns · $86m

Short-term assets $60mLonger-term assets $26m

What it owes, and who funded it · $86m

Short-term liabilities $26mLonger-term liabilities $17mShareholders' equity $44m

Short-term assets cover short-term liabilities $60m of assets due within a year against $26m of liabilities due within a year.
Short-term assets cover long-term liabilities $60m short-term assets against $17m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$25m against $625,000 of interest.

From Mediwound Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: MDWD vs PRQR CTMX vs MDWD CELU vs MDWD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mediwound Ltd.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mediwound Ltd.